IDH1 Mutation

Explore clinical trials studying IDH1 Mutation. Study availability and eligibility vary by location and protocol.

9 public trials 5 recruiting studies

Refine in advanced search Browse all conditions

IDH1 Mutation trial results

Recruiting

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

NCT07471841

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, IDH1 Mutation, +6 more
Locations: Atrium Health Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States

View Trial Details

Recruiting

Ivosidenib as Post-HSCT Maintenance for AML

NCT06707493

Conditions: Acute Myeloid Leukemia (AML), Hematologic Diseases, Hematopoietic Stem Cell Transplant (HSCT), +7 more
Locations: Emory University Hospital Atlanta, Georgia, United States

Massachusetts General Hospital Boston, Massachusetts, United States

Dana Farber Cancer Institute Boston, Massachusetts, United States

Ohio State University Wexner Medical Center- James Cancer Hospital Columbus, Ohio, United States

View Trial Details

Recruiting

Study of Olutasidenib and Temozolomide in HGG

NCT06161974

Conditions: Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, +36 more
Locations: Children's Hospital Colorado Aurora, Colorado, United States

Children's National Medical Center Washington D.C., District of Columbia, United States

University of Miami Hospital and Clinics Miami, Florida, United States

Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States

View all 20 locations

View Trial Details

Recruiting

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

NCT06611839

Conditions: AML, IDH1 Mutation, Treatment
Locations: Blood Diseases Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

NCT06782542

Conditions: Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations: University of Miami Miami, Florida, United States

View Trial Details

Not Yet Recruiting

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

NCT07664839

Conditions: Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China

View Trial Details

Completed

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

NCT04056910

Conditions: Advanced Solid Tumor, Glioma, IDH1 Mutation, +7 more
Locations: UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States

View Trial Details

Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

NCT03914742

Conditions: Astrocytoma, Glioblastoma, Glioma, +12 more
Locations: UAB Comprehensive Cancer Center Birmingham, Alabama, United States

University of California, Los Angeles Los Angeles, California, United States

Yale University New Haven, Connecticut, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States

View Trial Details

Active, Not Recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

NCT05406700

Conditions: Glioma, Glioma, Malignant, IDH1 Mutation, +10 more
Locations: Massachusetts General Hospital Boston, Massachusetts, United States

View Trial Details

IDH1 Mutation

IDH1 Mutation trial results

Related conditions